Inventiva Appoints Chris Benecchi as Chief Operating Officer

Inventiva, a clinical-stage biopharmaceutical company, has announced the appointment of Chris Benecchi as Chief Operating Officer. With extensive experience in biopharmaceutical leadership, Benecchi is set to lead Inventiva as it approaches the Phase 3 study results of lanifibranor, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). Results are expected in Q4 2026, with a potential U.S. launch targeted for 2028, pending regulatory approval.

CEO Andrew Obenshain highlighted lanifibranor's potential in providing a differentiated treatment for MASH. Benecchi's experience is considered particularly relevant as Inventiva prepares for potential commercialization stages. Previously, Benecchi served as CEO of Motric Bio and held senior roles at Sage Therapeutics and other major pharmaceutical companies.